When AI Becomes Part of Medicine: Why CMS’s AI Questions Matter Now - Epstein Becker Green

The U.S. Centers for Medicare & Medicaid Services (CMS) has begun asking targeted questions about the integration of artificial intelligence in healthcare, marking a potential turning point in regulatory oversight. The questions, highlighted in a recent analysis by Epstein Becker Green, suggest that CMS is evaluating how AI systems are validated, monitored, and deployed in clinical settings. This comes as healthcare providers increasingly adopt AI for diagnostics, treatment planning, and administrative tasks, raising concerns about patient safety, data privacy, and algorithmic bias.

The move indicates that CMS may be preparing to formalize guidelines or requirements for AI use in federally funded healthcare programs. Such a shift could have far-reaching implications for developers, hospitals, and insurers, who would need to ensure their AI systems meet new standards for transparency, accountability, and performance. The questions also reflect broader concerns about the reliability of AI in high-stakes medical decisions, where errors could have life-or-death consequences.

Healthcare AI has seen rapid growth in recent years, with tools like diagnostic imaging assistants and predictive analytics becoming commonplace. However, the lack of clear regulatory frameworks has left many stakeholders uncertain about compliance and liability. CMS’s intervention could provide much-needed clarity but may also impose additional burdens on innovators in the space.